LARINEX Tablet

•Seasonal allergic rhinitis

•Perennial allergic rhinitis

•Chronic idiopathic urticaria The recommended dose of LARINEX (Desloratadine) tablets is one 5mg tablet once daily with or without a meal.

Patients with renal and hepatic impairment:

In patients with renal or hepatic impairment, a starting dose of one 5mg tablet every other day is recommended based on pharmacokinetic data.

Paediatric use:

LARINEX (Desloratadine) tablets are not indicated for children under 12

Desloratadine is contraindicated in patients who have shown hypersensitivity or idiosyncrasy to desloratadine, to loratadine or to any of the excipients.

fatigue, headache and dry mouth. Other adverse effects reported very rarely were: Dizziness, somnolence, insomnia, tachycardia, palpitations, abdominal pain, nausea, vomiting, dyspepsia, diarrhoea, elevations of liver enzymes, increased bilirubin, hepatitis, myalgia, hypersensitivity reactions ^such as anaphylaxis, angioedema. dyspnoea, pruritus, rash and urticaria).

Pregnancy

There are no adequate and well-controlled studies of desloratadine in pregnant women. Desloratadine should be used during pregnancy only if the potential benefit justifies the risk to the fetus.

Nursing Mothers

Desloratadine passes into human breast milk; therefore, a decision should be made whether to discontinue desloratadine. taking into account the importance of the drug to the mother.

Renal impairment

Dosage adjustment for patients with renal impairment is recommended. (See the package insert about details.)

Hepatic Impairment

Dosage adjustment for patients with hepatic impairment is recommended. (See the package insert about details.)

Desloratadine inhibited histamine release from human mast cells in vitro.